Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Notes Payables: 2015-2021

Historic Notes Payables for Sunshine Biopharma (SBFM) over the last 7 years, with Dec 2021 value amounting to $1.9 million.

  • Sunshine Biopharma's Notes Payables rose 131.58% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.9 million, marking a year-over-year increase of 131.58%. This contributed to the annual value of $1.9 million for FY2021, which is 131.58% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Notes Payables of $1.9 million as of FY2021, which was up 131.58% from $820,454 recorded in FY2020.
  • In the past 5 years, Sunshine Biopharma's Notes Payables registered a high of $1.9 million during FY2021, and its lowest value of $419,663 during FY2018.
  • Its 3-year average for Notes Payables is $1.1 million, with a median of $820,454 in 2020.
  • As far as peak fluctuations go, Sunshine Biopharma's Notes Payables surged by 257.16% in 2017, and later declined by 29.65% in 2018.
  • Sunshine Biopharma's Notes Payables (Yearly) stood at $596,577 in 2017, then declined by 29.65% to $419,663 in 2018, then spiked by 39.71% to $586,307 in 2019, then spiked by 39.94% to $820,454 in 2020, then soared by 131.58% to $1.9 million in 2021.